Dexmedetomidine is an alpha2-agonist that has a similiar mechanism of action to clonidine. Short half-life and no respiratory depression make it possibly more effective than propofol in procedural sedation. Cost/Availability are the biggest barriers. Transient bradycardia is also possible but the actual incidence of clinically significant bradycardia is not yet elucidated.
I am still awaiting the first emergency department study looking at dexmedetomidine for procedural sedation.
A recent article actually brought up the possibility of utilizing it intranasally which could have some tantalizing pediatric applications.
